N
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
Price:
19.41 USD
3.13%
Market Closed
Updated:
May 29, 2024
NewAmsterdam Pharma Company NV
Operating Income
|
NewAmsterdam Pharma Company NV
Operating Income Peer Comparison
Comparables:
PHARM
PRQR
QURE
ARGX
MRUS
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
N
|
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
|
Operating Income
-€3.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Operating Income
-$8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Operating Income
-€30.5m
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Uniqure NV
NASDAQ:QURE
|
Operating Income
-$263m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-22%
|
|
|
argenx SE
XBRU:ARGX
|
Operating Income
-$592.1m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
|
|
Merus NV
NASDAQ:MRUS
|
Operating Income
-$166.6m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
See Also
What is NewAmsterdam Pharma Company NV's Operating Income?
Operating Income
-3.9m
EUR
-3.9m
EUR
Based on the financial report for Dec 31, 2022, NewAmsterdam Pharma Company NV's Operating Income amounts to -3.9m EUR.
What is NewAmsterdam Pharma Company NV's Operating Income growth rate?
Operating Income CAGR 1Y
-188%
-188%
Over the last year, the Operating Income growth was -188%.
You don't have any saved screeners yet
